Advertisements



Marker Therapeutics reports interim results of MultiTAA T Cell Therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 21st, 2019

Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study.....»»

Category: earningsSource: benzingaAug 14th, 2019

Marker Therapeutics: A Cell Therapy Biotech Thinking Outside Of The Box

Marker Therapeutics: A Cell Therapy Biotech Thinking Outside Of The Box.....»»

Category: topSource: seekingalphaJun 19th, 2019

TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today reported financial re.....»»

Category: earningsSource: benzingaApr 1st, 2019

TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade

TapImmune, Inc. (NASDAQ: TPIV) will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade.....»»

Category: blogSource: benzingaJun 2nd, 2018

Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment

Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»

Category: topSource: marketwatchJun 27th, 2018

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results

ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results -Ongoing Exploration of Strategic Opportunities- -Continued Progress in Stem-to-T-Cell.....»»

Category: earningsSource: benzingaAug 13th, 2018

Rancho Cordova"s Cesca Therapeutics reports $27.2 million loss on impairment of assets

Cesca Therapeutics Inc., a Rancho Cordova-based cell therapy company, said it incurred $27.2 million in charges against earnings last quarter for impairment in the value of assets. The impairment charges include $12.7 million to goodwill and $14.5.....»»

Category: topSource: bizjournalsAug 13th, 2018

Athersys reports "positive" results from study of MultiStem cell therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 23rd, 2019

Cytori Therapeutics announces results from Cytori Cell Therapy trial published

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 31st, 2019

Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018

LONDON, Feb. 25, 2019 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell thera.....»»

Category: earningsSource: benzingaFeb 25th, 2019

NeuBase Therapeutics Reports Financial Results for Fiscal Year 2019

PITTSBURGH, Jan. 09, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing ne.....»»

Category: earningsSource: benzingaJan 9th, 2020

Applied Therapeutics reports results of Phase 2 ACTION-Galactosemia study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 8th, 2020

Euro Tech Holdings Company Limited Reports Interim Results For The Six Months Ended June 30, 2019

HONG KONG, Dec. 23, 2019 /PRNewswire/ -- Euro Tech Holdings Company Limited (NASDAQ:CLWT) today reported its unaudited financial .....»»

Category: earningsSource: benzingaDec 23rd, 2019

VistaGen Therapeutics reports results of AV-101 in treating veteran suicide

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 19th, 2019

Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019

Topline results from the NORSE 1 study.....»»

Category: earningsSource: benzingaDec 19th, 2019

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019

Summit Therapeutics plc(‘Summit', the ‘Company' or the ‘Group') Summit Therapeutics Reports Financial Results and Operational Pr.....»»

Category: earningsSource: benzingaDec 17th, 2019

OncoSec reports interim results from KEYNOTE-890 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 13th, 2019

RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, C.....»»

Category: earningsSource: benzingaDec 11th, 2019

Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

- Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivo.....»»

Category: earningsSource: benzingaDec 10th, 2019

Precision BioSciences stock rises on early-stage CAR-T trial data

Shares of Precision BioSciences Inc. are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell therapy.....»»

Category: topSource: marketwatchDec 9th, 2019